ANIP Form 144: Insider Plans Sale of 6,937 Shares ($611.6K)

Q: What does the ANIP Form 144 disclose?

This Form 144 discloses a proposed sale of 6,937 common shares through Morgan Stanley Smith Barney with aggregate market value of $611,644.31 and an approximate sale date of 08/18/2025 .

Q: How many ANIP shares are outstanding and what percentage does the sale represent?

The filing reports 21,688,772 shares outstanding; the proposed sale of 6,937 shares represents approximately 0.032% of outstanding common stock.

Q: When were the shares being sold originally acquired?

The shares were acquired as restricted stock: 2,527 shares on 08/21/2024 and 4,410 shares on 05/21/2025 .

Q: Were there any other securities sold by this person in the past three months?

The filing states "Nothing to Report" for securities sold during the past three months by the person for whose account the securities are to be sold.

Q: Through which broker will the ANIP shares be sold?

The broker named in the filing is Morgan Stanley Smith Barney LLC , Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.

[144] ANI Pharmaceuticals, Inc. SEC Filing

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

144

Rhea-AI Filing Summary

ANI Pharmaceuticals (ANIP) Form 144 notice discloses a proposed sale of 6,937 common shares held by an insider through Morgan Stanley Smith Barney LLC, with an aggregate market value of $611,644.31 based on the filing. The shares represent a small portion of the company's outstanding common stock (21,688,772 shares outstanding) and the proposed sale is slated to occur on 08/18/2025 on NASDAQ.

The filing also lists the acquisition history for the shares being offered: 2,527 restricted shares acquired on 08/21/2024 and 4,410 restricted shares acquired on 05/21/2025, both issued by the company. No securities were reported sold by the person in the prior three months on this form, and the filer certifies that they have no undisclosed material adverse information.

Positive

Regulatory compliance: The filer submitted a complete Rule 144 notice including broker, share count, market value, and acquisition history
Transparency: Acquisition dates and number of restricted shares are disclosed, enabling clear tracing of grant origins

Negative

Insider sale: An affiliate intends to sell 6,937 shares valued at $611,644.31, which is a disposition of insider-held equity

Insights

TL;DR: Routine Rule 144 disclosure of insider sale; documentation aligns with restricted-stock vesting and brokerage placement.

The filing provides the required Rule 144 notice for a proposed sale of 6,937 shares through Morgan Stanley Smith Barney, documenting acquisition dates and that the shares were issued as restricted stock by the issuer. From a compliance perspective, the form contains the essential elements: broker details, number of shares, market value, outstanding shares, acquisition dates, and a certification regarding material nonpublic information. There are no reports of prior sales in the past three months, which simplifies aggregation questions under Rule 144(e).

TL;DR: Insider sale size is immaterial to capitalization; transaction appears administrative rather than market-moving.

The proposed sale equals roughly 0.032% of the reported outstanding common shares, indicating the transaction is unlikely to materially affect market supply or the company鈥檚 capitalization. The shares originated from restricted-stock issuances on two dates in 2024 and 2025, consistent with vesting/compensation events. The disclosure is standard for officer/affiliate liquidity events and contains no additional market-impacting details such as planned block trades or large-volume arrangements.

08/18/2025 - 04:18 PM

144: Filer Information

Filer CIK

Filer CCC

Is this a LIVE or TEST Filing?

LIVE TEST

Submission Contact Information

Name

Phone

E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold

Name and Address of the Broker

Number of Shares or Other Units To Be Sold

Aggregate Market Value

Number of Shares or Other Units Outstanding

Approximate Date of Sale

Name the Securities Exchange

Common

Morgan Stanley Smith Barney LLC Executive Financial Services
1 New York Plaza
8th Floor
New York NY 10004

6937

611644.31

21688772

08/18/2025

NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class

Date you Acquired

Nature of Acquisition Transaction

Name of Person from Whom Acquired

Is this a Gift?

Date Donor Acquired

Amount of Securities Acquired

Date of Payment

Nature of Payment *

Common

08/21/2024

Restricted Stock

Issuer

2527

08/21/2024

Not Applicable

Common

05/21/2025

Restricted Stock

Issuer

4410

05/21/2025

Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Source:

FAQ

What does the ANIP Form 144 disclose?

This Form 144 discloses a proposed sale of 6,937 common shares through Morgan Stanley Smith Barney with aggregate market value of $611,644.31 and an approximate sale date of 08/18/2025.

How many ANIP shares are outstanding and what percentage does the sale represent?

The filing reports 21,688,772 shares outstanding; the proposed sale of 6,937 shares represents approximately 0.032% of outstanding common stock.

When were the shares being sold originally acquired?

The shares were acquired as restricted stock: 2,527 shares on 08/21/2024 and 4,410 shares on 05/21/2025.

Were there any other securities sold by this person in the past three months?

The filing states "Nothing to Report" for securities sold during the past three months by the person for whose account the securities are to be sold.

Through which broker will the ANIP shares be sold?

The broker named in the filing is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.

AG真人官方

[144] ANI Pharmaceuticals, Inc. SEC Filing

Insights

144: Filer Information

Submission Contact Information

144: Issuer Information

144: Securities Information

144: Securities To Be Sold

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

ATTENTION:

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the ANIP Form 144 disclose?

How many ANIP shares are outstanding and what percentage does the sale represent?

When were the shares being sold originally acquired?

Were there any other securities sold by this person in the past three months?

Through which broker will the ANIP shares be sold?

NASDAQ:ANIP

ANIP Rankings

ANIP Latest News

ANIP Latest SEC Filings

ANIP Stock Data

AG真人官方

Trending News

[144] ANI Pharmaceuticals, Inc. SEC Filing

Insights

Securities Compliance Analyst neutral

Equity Capital Markets Specialist neutral

144: Filer Information

Submission Contact Information

144: Issuer Information

144: Securities Information

144: Securities To Be Sold

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

ATTENTION:

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the ANIP Form 144 disclose?

How many ANIP shares are outstanding and what percentage does the sale represent?

When were the shares being sold originally acquired?

Were there any other securities sold by this person in the past three months?

Through which broker will the ANIP shares be sold?

NASDAQ:ANIP

ANIP Rankings

ANIP Latest News

ANIP Latest SEC Filings

ANIP Stock Data